SLC29A1 and cholangiocarcinoma: The present findings indicate a predictive role of hENT1 for gemcitabine sensitivity in vitro, and highlight the importance of further immunohistochemical standardization and preclinical validation of the role of hENT1 in cholangiocarcinoma.